Prediction and monitoring of LULC shift using cellular automata-artificial neural network in Jumar watershed of Ranchi District, Jharkhand.

Jumar watershed of Ranchi district is agrarian in nature. The unplanned and exponentially growing urban sprawl has become one of the probable threats in achieving sustainable development goals (SDG-15). The purpose of this research study is to monitor the urban sprawl in Jumar watershed within three decades i.e. from the year 1990 to 2021. Land use land cover (LULC) change has been monitored using satellite data from LANDSAT (4, 5 and 8). Various indices are calculated like normalised difference vegetation index (NDVI), normalised difference built-up index (NDBI), normalised difference water index (NDWI) and built-up index (BUI) to monitor LULC change in the area. For prediction of urban sprawl, cellular automata and artificial neural network (CA-ANN) with GIS application technique is used. The model is validated by using Kappa coefficient. The prediction results showed increase in built-up area by 8.23 sq. km in the next decade. The built-up and barren land together increase up to 42.85 sq. km by 2030 and 34.61 sq. km in 2021. The NDVI for 3-decade period showed significant decrease in the healthy vegetation and increase in sparse vegetation. The NDBI showed a slight increase in urban area but massive increase in uncultivated and barren land. NDWI showed a decrease in area of the surface water. The LULC studies showed a major shift from healthy vegetation to agriculture and then to barren land. To assess the impact of urbanisation on water quality, water samples are taken seasonally from J1to J11 sampling locations and are analysed as per APHA procedure. The sites are classified as urban, semi urban and rural area as per their location. The water quality index (WQI) varied between 42.14 to 61.42 during pre-monsoon, 62.20 to 68.7995 during monsoon and 43.48 to 60.12 during post-monsoon. The quality of water is found poor in all seasons at all sampling sites. The water is found highly turbid and alkaline throughout the year. Overall, it can be concluded that the water needs to be pre-treated for drinking purposes throughout the year.

Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.

PURPOSE: We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (LVL) and non-LVL collections. METHODS: We performed a retrospective data analysis of all autologous HPC-A collections with the Optia® CMNC system (n = 93; LVL = 59, non-LVL = 34) since implementation at our institution and compared it with a similar number of concurrent collections utilizing the COBE® Spectra (n = 96; LVL = 68, non-LVL = 28). The population studied included multiple myeloma (62 patients/171 collections) and lymphoma (5 patients/18 collections). Mobilization was achieved using chemotherapy + G-CSF (n = 108), chemotherapy + G-CSF + plerixafor (n = 67), G-CSF alone (n = 10), or G-CSF + plerixafor (n = 4). Based on our minimum predicted collection formula and the collection goal, 7-30 L of whole blood was processed. Per protocol, a minimum of 2 days of collection was performed. RESULTS: HPC-A collected on Optia® CMNC had lower %HCT than those collected on COBE® Spectra (3.7 versus 4.3%, P = .029). There were no statistically significant differences between the two devices for other variables examined, including preapheresis WBC count and CD34+ cell count, procedure time, whole blood volume processed, collection efficiency (CE2), % platelet loss and throughput. CE2 for both devices was higher when <30 L of whole blood volume was processed. A linear correlation was noted between the preapheresis CD34+ cell count and CD34+ cells collected. No adverse events or bleeding episodes were noted, even when acetyl salicyclic acid (ASA) was given. CONCLUSIONS: Optia® CMNC system is equivalent to the COBE® Spectra, with significantly lower product HCT%.

Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.

Thrombotic thrombocytopenic purpura (TTP) results from a congenital or acquired deficiency of the von Willebrand factor (vWF)-cleaving protease ADAMTS13. The disease can be fatal and hence treatment should be initiated promptly. Therapeutic plasma exchange (TPE) remains the standard treatment along with adjunct therapies including steroids and immunosuppressive drugs. Addition of rituximab to TPE has been shown to be beneficial in refractory/relapsing TTP; however, TPE results in removal of rituximab from the circulation requiring more frequent dosing of rituximab to achieve a favorable outcome. The intermediate-purity plasma-derived Factor VIII concentrate (FVIII) Koate® contains the highest amount of ADAMTS13 activity yet reported and has been used successfully in treating congenital TTP. Here we report our experience with addition of this FVIII concentrate to rituximab, corticosteroids and TPE in three TTP patients with an ADAMTS13 inhibitor to permit withholding TPE for 48 h after rituximab infusion.

HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies.

BACKGROUND: Thrombotic microangiopathies (TMA) are a group of disorders with overlapping clinical features that require urgent intervention. Treatment is based on the recognition of the TMA type, which is often challenging. The aim of this study was to identify specific HLA associations with different TMA types to aid rapid diagnosis and appropriate treatment, since the HLA assay can be completed within five hours. METHODS: All 86 consecutive patients who presented to the University of Arkansas for Medical Sciences between May 2013 and January 2021 with a presumptive diagnosis of TMA were included in this study. HLA typing was performed and correlated with other clinical and laboratory studies. RESULTS: In comparison with other types of TMA, patients with acquired thrombotic thrombocytopenic purpura (aTTP) showed increased frequencies of HLA-DRB1*11, HLA-DQB1*03:01/19, HLA-DRB1*08 and HLA-DRB3. Combining the presence of these HLA associations with a PLASMIC score of 6 or more achieved a higher positive predictive value (90%) for identifying aTTP than the PLASMIC score alone (69%). In comparison with other TMA types, patients with aTTP showed decreased frequencies of HLA-DRB4, HLA-DRB1*07, HLA-DQB1*02. The HLA-DRB1*07/DQB1*02 was not observed in any aTTP patients (negative predictive value: 100%), and thus the presence of this haplotype essentially rules out aTTP. Further, HLA-DRB1*11/DQB1*03:01/19 was absent in atypical hemolytic uremic syndrome patients. CONCLUSION: HLA alleles can be used as an adjunct for the rapid assessment of TMA and can help to differentiate it from other primary and secondary forms of TMA, allowing for earlier definitive therapy.

Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease.

Acquired hemophilia is caused by acquired autoantibodies to 1 of the factors of the coagulation cascade, usually factor VIII or IX, and is an exceedingly rare phenomenon in children. The finding of an acquired factor VIII inhibitor in a pediatric patient with idiopathic multicentric Castleman disease has never been reported. Patients with acquired hemophilia can have life-threatening bleeds that are refractory to blood product support, requiring bypassing agents to manage bleeding symptoms. We present the novel finding of acquired hemophilia resulting from an autoantibody to factor VIII in a pediatric patient with idiopathic multicentric Castleman disease and discuss the optimal management of bleeding in a patient with acquired hemophilia.

Seventy-five years of service: an overview of the College of American Pathologists' proficiency testing program in histocompatibility and identity testing.

The Histocompatibility and Identity Testing Committee offers an overview of the College of American Pathologists' (CAP) Proficiency Testing (PT) program, commemorating its significant 75th anniversary in 2024. The CAP PT program has undergone significant growth and evolution over the years, ultimately achieving Centers for Medicare and Medicaid Services approval. In 1979, CAP's partnership with the American Association for Clinical Histocompatibility Testing marked a pivotal moment, leading to the creation of the first proficiency testing survey in 1980. This laid the foundation for various PT programs managed by the CAP Histocompatibility and Identity Testing Committee, including HLA antibody testing, HLA molecular typing, engraftment monitoring, parentage/relationship testing, HLA disease associations and drug risk, and HLA-B27 typing. Each program's distinctive considerations, grading methodologies, and future prospects are detailed here, highlighting the continual evolution of histocompatibility and identity testing PT to support emerging technologies and evolving laboratory practices in the field.

Combined Schwannoma and Kappa-Restricted Plasma Cell Neoplasm: A Case Report and Review of the Literature.

The patient is a 78-year-old woman with a popliteal soft tissue mass that was tender to palpation with shooting pain on physical examination. A schwannoma was seen on biopsy with subsequent excision demonstrating a concomitant kappa-restricted plasma cell neoplasm. Follow-up did not show evidence of a systemic plasma cell neoplasm. MRI studies showed no evidence of focal lesions, although PET-CT revealed presence of multiple lytic lesions. The patient is currently being monitored every six months. This case is the first kappa-restricted plasma cell neoplasm reported in association with a schwannoma and the first reported in the extremities.

Construction of integrated system for the treatment of Acid orange 7 dye from wastewater: Optimization and growth kinetic study.

In this work, an effort has been made to develop an integrated system (ozonation followed by biodegradation) for the treatment of Acid orange 7 (AO 7) dye. The process parameters such as pH (3.0-11) and ozone dosage (5-25 mg/L) were optimized and obtained as 3.0 and 25 mg/L, respectively to treat the AO 7 by ozonation. Similarly, the process parameters, namely pH (5.0-9.0) and temperature (25-45 °C) were optimized and found to be 7.0 and 35 °C, respectively by biological treatment. Bacillus sp. was found to be the most effective bacteria to remove the AO 7. An integrated system obtained an overall 98.7% removal of AO 7 under optimum conditions. Andrews-Haldane model was best to predict the experimental data and the bio-kinetic constants; µmax: 0.1875 day-1; Ks: 49.53 mg/L; Ki: 133.32 mg/L were obtained. The developed integrated system can be a promising option for the treatment of azo dye containing-wastewaters.

Human parvovirus B19 infection in an immunocompromised host.

Serologic testing may be negative in immunocompromised hosts due to inadequate IgG and IgM response. The classic bone marrow findings of viral inclusions and giant proerythroblasts are pathognomonic for active infection and should prompt initiation of therapy regardless of serologic results.

Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease.

Histiocyte-rich pseudotumors (HRPT) developing postchemoradiation therapy are a florid response to treatment and reparative change. Although these are benign processes, clinically and radiologically, these may mimic recurrent/relapsed disease. We describe a case of an adult male with history of diffuse large B-cell lymphoma (DLBCL), status postchemoradiation therapy, who developed HRPT at the site of original involvement, mimicking relapse of disease on positron emission tomography/computed tomography (PET/CT) imaging. This is one of the few reported cases of posttreatment HRPT. This entity is important to point out the limitations of PET/CT imaging in patients with lymphomas and metastatic disease and stresses the importance of an excisional biopsy for determining relapse and the need for further treatment.

Epitope Analysis Aids in Transplant Decision Making by Determining the Clinical Relevance of Apparent Pre-Transplant Donor Specific Antibodies (DSA).

Pre-transplantation work-up on a patient with end stage renal disease using Single Antigen Bead (SAB) testing showed significant anti-HLA-B*44:02 (>5,000 MFI) and anti-HLA-B*44:03 (>1,000 MFI) antibodies, with persistence on quarterly testing. No significant Class II anti-HLA antibodies were present. The patient received a potential offer from a living unrelated-donor expressing HLA-B*44:02. Based on the presence of anti-HLA-B*44:02 antibody, the crossmatch (XM) was predicted to be positive. However, the actual fluorescence cytometry crossmatch (FCXM) was negative. FCXM and Complement Dependent Cytotoxicity-XM (CDC-XM) studies with three surrogate donors who expressed HLA-B*44:02 (and no other potential confounding HLA types) were also negative. Additional assays were performed for detecting anti-HLA antibodies. Immucor® LSA® SAB analyses also revealed presence of anti-HLA-B*44:02 and anti-HLA-B*44:03 antibodies. However, One Lambda® Antigen Trays, C1q analysis, and iBeads®, did not detect elevated anti-HLA-B*44:02 and/or anti-HLA-B*44:03 antibodies. An extensive evaluation of all exposed and non-exposed epitopes expressed by the patient and the donor was performed to identify the non-shared epitopes between them. The donor specific antibody (DSA) pattern detected would be expected to conform to non-shared epitopes; however, non-shared "exposed" epitopes were not present in the DSA antibody pattern. Whereas, the apparent DSA antibody pattern consisted of antibodies to "non-exposed" epitopes. Altogether, it was concluded that the anti-HLA-B*44:02 antibody detected by SAB testing was directed against some denatured component(s) (non-exposed) of the HLA antigen attached to the SAB, and would not be clinically significant. The patient received the transplant and the post-transplant course has been uneventful for greater than 5 years. This case emphasizes: (1) A significant number of SAB may have denatured HLA molecules attached to them (2) The DSA and non-DSA anti-HLA antibody patterns should be evaluated for the expected epitope components to determine the clinical relevance. Additional testing should be considered to help with these analyses (3) The FCXM remains the "gold standard" for making the final decision to transplant, since the "stringent" use of a "predicted" positive XM using apparent DSA detected by SAB analysis may exclude XM-compatible donors.

Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities.

The epidural space is an uncommon site for involvement by hematolymphoid malignancies, and may present unexpectedly with neurological symptoms related to spinal cord compression. Our objective was to review the clinical and pathologic features of cases with initial presentations of cord compression, subsequently diagnosed as a hematolymphoid malignancy after pathologic examination. Review of the Department of Pathology's archives revealed 15 patients who presented with spinal cord compression due to epidural hematolymphoid malignancies between 2008-2019. These cases involved five primary epidural lymphomas, including an ALK-negative anaplastic large T-cell lymphoma previously not reported at this site, three diffuse large B cell lymphomas, one B-lymphoblastic lymphoma, four cases of myeloid sarcoma, one case with a previous history of acute myeloid leukemia, five cases with plasma cell neoplasms and epidural lesions as the initial presentation of plasma cell myeloma, one case showing aberrant T-cell marker expression, and one case being a histiocytic sarcoma that is rarely reported in the spine. A hematolymphoid malignancy was suspected clinically or radiologically in only five of these cases. These cases represent the spectrum of hematolymphoid malignancies that can involve the epidural space and present for the first time with cord compression, resulting in clinical, radiological and pathologic diagnostic challenges. Their diagnoses require a high degree of awareness, suspicion, and thorough histologic evaluation with ancillary studies for appropriate disease classification and therapeutic intervention. To our knowledge, this is one of the largest and most diverse of such series in the English language literature.

Vitamin B12 deficiency mimicking acute leukemia.

Vitamin B12 deficiency can cause extensive hematologic alterations such as pancytopenia, macrocytosis, hypersegmentation of neutrophils, and hypercellular bone marrow with blastic differentiation. These dysplastic changes can sometimes be so profound that they mimic myelodysplastic syndromes or even acute leukemia, leading to extensive workup and aggressive treatment measures. We present a patient who was referred to our tertiary care medical center for treatment of suspected acute myeloid leukemia on the basis of peripheral smear and bone marrow biopsy findings, and induction chemotherapy was considered. However, the patient was found to have vitamin B12 deficiency, with improvement in pancytopenia and blastic changes with parenteral vitamin B12 supplementation. This highlights the importance of recognizing that dysplastic changes in patients with vitamin B12 deficiency could be misleading.

ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma.

ADAMTS13 testing plays a critical role in confirming the clinical diagnosis of acquired idiopathic thrombotic thrombocytopenic purpura (TTP) and distinguishing it from other forms of thrombotic microangiopathies (TMA). Serial measurements of ADAMTS13 activity and inhibitor levels are also helpful in determining response to treatment and/or subsequent relapses. Numerous ADAMTS13 assays have been developed recently, including some with rapid turnaround times. Despite the good inter-assay correlation of different ADAMTS13 methodologies in published case studies, discrepancies have been shown to occur. Here we present a case where discrepant results were obtained using two different assays, posing a clinical treatment dilemma.

Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series.

OBJECTIVE: To explore the benefits of adding eculizumab for the treatment of refractory autoimmune thrombotic thrombocytopenic purpura (iTTP) with complement dysregulation. PATIENTS AND METHODS: From January 1, 2014, through July 1, 2017, we identified patients with iTTP defined by ADAMTS13 (disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) levels less than 5% and the presence of ADAMTS13 inhibitor. Patients who progressed after receiving standard of care management for iTTP were subjected to a comprehensive evaluation to look for evidence of complement activation. Herein, we share our single-institute experience regarding the clinical course and treatment algorithm for 3 patients with refractory iTTP. RESULTS: All the patients had clinical deterioration despite treatment with plasma exchange, corticosteroids, rituximab, and vincristine, which prompted us to look for evidence of complement activation and associated genetic mutations. Complement-related genetic aberrations were present in all 3 patients, who had had different degrees of complement activation. The first 2 patients did not benefit from eculizumab when treatment was started before complete clearance of inhibitors to ADAMTS13. However, they had durable remissions when eculizumab was introduced after clearance of ADAMTS13 inhibitors. The third patient started eculizumab therapy after inhibitor levels were undetectable. CONCLUSION: We found eculizumab therapy to be effective in all 3 patients. However, its efficacy was prominent only after clearance of antibodies against ADAMTS13 via therapeutic plasma exchange.

Acetylsalicylic Acid During Leukapheresis Reduces the Incidence of Clotting in Hematopoietic Progenitor Cell Products.

INTRODUCTION: Clots may be seen during hematopoietic progenitor cell (HPC) collection or on product arrival to the cell therapy processing laboratory. We have always given one 81 mg acetylsalicylic acid (ASA) when clotting is seen during collection if there is no allergy, but hypothesized that the incidence of clotting would decrease if ASA was given to all autologous collectors with a platelet count of ≥80×109/L prior to collection (pre-emptively). METHODS: Autologous HPC were collected using the Spectra Optia instrument or Cobe Spectra instrument (Terumo BCT®, Lakewood, CO) with heparinized citrate. A retrospective review was performed to determine the total number of HPC products, including products with clots, collected between September 2010 and August 2013 (group 1). All autologous HPC collectors from September 2013 onwards were given ASA pre-emptively if their platelet count was ≥80×109/L (group 2), and a similar review was performed in this group. We included the cell density and platelet count of the HPC products and the platelet count of the patient in the data collected. We reviewed procedure notes for adverse events or bleeding. RESULTS: A total of 2574 HPC products were collected between September 2010 and August 2013; clotting was observed in 66 HPC products (66/2574; 2.56%). A total of 1906 HPC products were collected between November 2013 and October 2016; clotting was observed in 24 HPC products (24/1906; 1.25%). Thus an overall reduction was seen in incidence of clotting between groups 1 and 2 (2.56% versus 1.25; P=0.002). Since not all collectors in group 2 received pre-emptive ASA, we reviewed the incidence of clotting within this group. A decrease in incidence of clots was noted with preemptive ASA (group 2A) (5/512, 0.97%) versus no ASA (group 2B) (19/1394, 1.36%), but this was not statistically significant. The mean cell density of the HPC products did not differ significantly between these two groups (group 2A and 2B) but a higher platelet count was observed in the pre-emptive ASA group as expected (group 2A) (P=0.004). Multivariate logistic analysis after adjusting for platelet count of the HPC products showed a trend towards reduced incidence of clotting in the pre-emptive ASA group (group 2A); however no association was seen after adjusting for the cell density of HPC products, nor was an association between patient's platelet count and incidence of clotting seen. None of the collectors who received ASA suffered any adverse events, including bleeding. CONCLUSION: We observed an overall reduction in the incidence of clotting in our HPC products after initiating pre-emptive ASA usage (2.56% versus 1.25%; P=0.002). A trend towards lower incidence of clotting was noted when further analysis was performed to include pre-emptive ASA usage and platelet count of the HPC products. Although the overall incidence of clotting was very small (<3.0%), giving ASA pre-emptively further reduced the incidence of clotting and thus prevented wastage/cell loss of HPC products.